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Abstract
Background: The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT)
are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world
descriptions of cinacalcet prescription discontinuation and reinitiation in European hemodialysis patients are
lacking. To address this knowledge gap, we used Dialysis Outcomes and Practice Patterns Study (DOPPS) data,
based on dialysis facility medical records, from seven European countries to estimate rates and predictors of
cinacalcet prescription discontinuation and reinitiation in hemodialysis patients and to describe the trajectories of
CKD-MBD laboratory values after discontinuation.
Methods: Cox regression analyses were used to predict (1) cinacalcet discontinuation among 613 patients with ≥3
consecutive months without cinacalcet prescription immediately prior to a new cinacalcet prescription and (2)
cinacalcet reinitiation among 415 patients with a newly discontinued cinacalcet prescription immediately after ≥3
consecutive months of prescribed use.
Results: Cinacalcet was discontinued in 21 and 35% of new users after 6 and 12 months, respectively. Cinacalcet
was reinitiated in 38 and 49% of newly-discontinued users after 6 and 12 months, respectively. Predictors of
discontinuation included lower parathyroid hormone (PTH) in the previous month (< 150 pg/ml vs. 150–299, HR =
2.57 [95% CI: 1.52–4.33]) and lower serum calcium in the previous month (< 8.4 mg/dl vs. 8.4–10.19, HR = 1.67 [95%
CI: 1.08–2.59]). Predictors of reinitiation included higher PTH in the previous month (300–599 pg/ml vs. 150–299, HR
= 1.88 [95% CI = 1.19–2.97]; 600+ pg/ml, HR = 3.02 [95% CI = 1.92–4.76]). After cinacalcet discontinuation, mean
serum PTH increased from 408 to 510 pg/ml, mean serum calcium briefly rose from 9.12 to 9.22 mg/dl before
declining to 9.06 mg/dl, and mean serum phosphorus showed little change.
Conclusions: Nephrologist discontinuation of cinacalcet therapy is common in European countries. Additional
research is needed to identify optimal cinacalcet treatment strategies for SHPT management, including comparisons
of intermittent cinacalcet therapy versus sustained treatment with reduced dose or frequency.
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Background
Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD) and
end-stage renal disease (ESRD) that can lead to elevated
parathyroid hormone (PTH), serum calcium, and serum
phosphorus levels [1–3]. Estimates of SHPT prevalence
vary substantially, with PTH levels > 300 pg/ml in 30–
50% of hemodialysis patients in most countries [4].
SHPT is associated with increased risks of fractures, car-
diovascular disease, and mortality in dialysis patients [5–
7] and is typically managed using a variety of treatments,
including changes to dietary intake or dialysis prescrip-
tion, vitamin D compounds, calcimimetics, and phos-
phate binders [8, 9].
Cinacalcet (Amgen Inc., Thousand Oaks, CA United
States [10]) is an oral calcimimetic agent used in ap-
proximately 15–20% of the European hemodialysis
population [7, 11]. It directly reduces PTH levels with an
additional resultant effect of decreasing serum calcium
and phosphorus levels [12, 13]. As with most chronically
administered medications, the putative benefits of cina-
calcet therapy are thought to manifest when patients are
taking it consistently as prescribed, and consequently,
the benefits of cinacalcet may not be fully realized when
not remaining on therapy [14].
Medication non-adherence – failure to follow timing,
dosage, or frequency recommendations –precludes pa-
tients from attaining the greatest benefits of their pre-
scribed therapy, and has been associated with increased
mortality, hospitalizations, and health care costs [15–
17]. A very broad range in medication non-adherence
has been estimated in hemodialysis patients [18], with
estimates ranging from 3 to 80% across 19 studies [19],
and 13 to 99% across 44 studies [20]. Although medica-
tion non-adherence can be difficult to accurately meas-
ure, it is meaningful to understand variations across
nephrologists in rates of starting and stopping cinacalcet
prescriptions, and related factors. Despite evidence of
the benefits of managing SHPT-related biochemistries
with cinacalcet, post-marketing studies in real-world set-
tings - largely in the US - indicate that treatment discon-
tinuation is common [21–24], and is associated with
demographic, clinical, and financial factors.
Compared to those in the US, most studies of cinacal-
cet discontinuation in the European dialysis population
have been more limited in size and scope. In a retro-
spective cohort study of 5193 incident European
hemodialysis patients receiving treatment from a single
large-chain provider, the authors reported that 23% of
cinacalcet users discontinued treatment (defined as ≥45
consecutive prescription-free days) during a maximum
of 12months of follow-up [25]. Additional work is
needed to obtain a broader understanding of real-world
cinacalcet discontinuation in Europe, associated factors,
and fluctuations in PTH, calcium, and phosphorus levels
following discontinuation – particularly in view of the
differing health care delivery structures for hemodialysis
patients across various European countries.
To help inform this knowledge gap and inform key as-
pects of real world cinacalcet prescription in
hemodialysis patients, we have examined the rates of
European nephrologists discontinuing and re-initiating
cinacalcet prescriptions for their hemodialysis patients,
along with assessing numerous factors to understand
key predictors of cinacalcet discontinuation and reinitia-
tion prescriptions by European nephrologists. Our ana-
lyses are based upon data abstracted from dialysis
facility medical records in national samples of
hemodialysis facilities and patients from seven European
countries participating in the Dialysis Outcomes and
Practice Patterns Study (DOPPS). Our study goals are
to: (1) describe rates of cinacalcet prescription discon-
tinuation and reinitiation based upon a patient’s medical
record, (2) identify factors associated with cinacalcet
prescription discontinuation and reinitiation, and (3) de-
scribe the trajectories of PTH, calcium, and phosphorus




The study population for our analysis was drawn from
all adult patients receiving center-based hemodialysis at
a DOPPS participating facility during phases 4 (2009–
2011) and 5 (2012–2015) from Belgium (phase 4 only),
France, Germany, Italy, Spain, Sweden (phase 4 only),
and the United Kingdom (UK). DOPPS 5 follow-up time
in France and Spain was reduced due to a mid-phase
change in study protocol. DOPPS was approved by a
central institutional review board (IRB) in the US, with
additional IRB study approval and patient consent ob-
tained to meet national and local ethics committee regu-
lations at each study site. Patients were required to
survive at least 4 months after enrollment in their re-
spective DOPPS phase; this minimum survival require-
ment ensured sufficient determination of cinacalcet
non-exposure enabling the retrospective identification of
new (not necessarily first) users, and allowed for the
measurement of baseline covariates.
Detailed clinical and laboratory data were collected
monthly from dialysis facility medical records. In phase
4, prescription status for cinacalcet and other renal med-
ications was indicated on the dialysis facility’s patient
medication list as of the last day of each study month; in
phase 5, prescription status was indicated based upon
any active prescription for cinacalcet on the medication
list during each study month. Single months during
follow-up with missing cinacalcet prescription data used
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the prior month value (i.e., last -observation -carry-for-
ward; < 5% of months). Follow-up periods containing
two consecutive months with missing cinacalcet pre-
scription data were censored as of the first missing
month.
Cohort identification
Patients eligible for the analysis of cinacalcet discontinu-
ation (“new-user cohort”) were defined as having a
period of at least 3 consecutive months without cinacal-
cet prescription (baseline period) immediately prior to a
month containing a new cinacalcet prescription (this
month is referred to as the ‘index’ month; Fig. 1a).
Follow-up time began with the first monthly record after
the index month and continued until the cinacalcet pre-
scription was discontinued (i.e., removed from the medi-
cation list). Follow-up was censored if the patient
received a parathyroidectomy or was lost to follow-up
(i.e. due to death or departure from the study facility), or
DOPPS follow-up was terminated for administrative rea-
sons. Patients with parathyroidectomy prior to start of
follow-up were excluded.
Patients eligible for the analysis of reinitiation after
discontinuation and post-discontinuation trajectories of
CKD-mineral and bone disorder (MBD) lab markers
(“newly-discontinued-user cohort”) were defined as hav-
ing a period of at least 3 consecutive months with a
cinacalcet prescription immediately prior to a month in
which the prescription was discontinued (i.e., ‘index’
month; Fig. 1b). Follow-up time began with the first
monthly record after the index month and continued
until a new cinacalcet prescription was started (i.e.,
added to the medication list). Follow-up was censored if
the patient received a parathyroidectomy or was lost to
follow-up (i.e. due to death or departure from study fa-
cility), or DOPPS follow-up was terminated. Patients
with parathyroidectomy prior to start of follow-up were
excluded. We additionally conducted two sensitivity
analyses to explore alternative definitions for the
newly-discontinued-user cohort: (1) reducing the base-
line period to 1 month of cinacalcet prescription, instead
of 3 months, prior to discontinuation, and (2) restricting
to patients in the new-user cohort (defined above) who
experienced a discontinuation. No substantial differences
in reinitiation rates were observed using these alternative
definitions, so we reported only the primary results.
Statistical analyses
We estimated crude (unadjusted) discontinuation and
reinitiation rates by dividing the number of first discon-
tinuation or reinitiation events by the total number of
follow-up months at risk of each outcome. Rate esti-
mates are expressed per month, and are provided overall
and by country. We additionally report the proportion
of patients discontinuing or resuming cinacalcet treat-
ment at each follow-up month using Kaplan-Meier
methods. Comparisons of these curves were carried out
using log-rank tests.
Demographic, clinical history, and treatment variables
were ascertained at a single time during the baseline
period (defined above for each cohort) or updated during
follow-up using a 1-month lag (“time-dependent”) to en-
sure temporal precedence of predictor values with respect
to outcomes. For time-dependent covariates with missing
data, we imputed intermittent missing values encountered
during follow-up periods for up to 2 consecutive months
using the last-observation-carry-forward method. No
values were imputed for months that occurred after a
Fig. 1 Cohort identification diagram. Panel a denotes the treatment pattern required for entry into the "new-user" analysis cohort. Panel b
denotes the treatment pattern required for entry into the "newly-discontinued-user" analysis cohort
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subject ceased study observation. This method is
consistent with clinical treatment decision-making in
regard to infrequently measured variables.
We examined crude and adjusted associations of dis-
continuation and reinitiation with demographic and clin-
ical factors using Cox proportional hazards regression
models. Non-proportionality was assessed using stand-
ard graphical and statistical methods. Baseline covariates
adjusted for in models were age, years with ESRD (vin-
tage), sex, body mass index (BMI) and 13 summary co-
morbid conditions (coronary artery disease, congestive
heart failure, other cardiovascular disease, cancer [other
than skin], diabetes, hypertension, recent GI bleeding,
psychiatric disorder [depression, bipolar disorder, schizo-
phrenia, and alcohol or substance abuse], peripheral vas-
cular disease, lung disease, neurologic disorder,
recurrent cellulitis, cerebrovascular disease). CKD-MBD
laboratory values (serum levels of calcium, phosphorus,
and PTH), clinical status measures (hospitalization,
serum albumin level) and concurrent prescriptions of re-
lated CKD-MBD treatments (vitamin D, phosphate
binders) were measured at baseline and during follow-up
as time-dependent variables. Continuous variables were
categorized using clinically meaningful cut-points.
Among patients in the newly-discontinued-user co-
hort, we estimated the trajectories of CKD-MBD labora-
tory values (calcium, phosphorus, PTH) for 12 months
in two ways: (1) censoring follow-up at reinitiation of
cinacalcet treatment (prescription) or loss to follow-up
for any reason (n = 367); and (2) restricting to patients
with 12 months of cinacalcet-free follow-up (n = 81). We
used LOESS (LOcal regrESSion) curves to depict the
smoothed trend, and 95% confidence limits for the
means are reported.
Results
Cinacalcet discontinuation in the new-user cohort
Overall, new cinacalcet prescriptions were initiated in
613 hemodialysis patients during the study, and these
patients contributed 5454 months of follow-up to the
discontinuation analysis. Therapy was discontinued in
172 patients (Table 1, left panel). The overall discontinu-
ation rate was 0.032/month and ranged two-fold by
country, from 0.021/month in Sweden to 0.045/month
in Belgium. The overall proportion of patients discon-
tinuing cinacalcet was 21% after 6 months and 35% after
12 months; variability among countries at 12 months
ranged from 21% in Sweden to 46% in Belgium (Fig. 2).
Patients who discontinued cinacalcet had a higher preva-
lence of heart- and vascular-related comorbid conditions,
but lower median PTH levels at initiation [430 pg/mL
(IQR: 317,749)] compared to that for patients who did
not discontinue cinacalcet [507 pg/mL (IQR: 340,780)]
(Table 2).
Adjusted associations between cinacalcet discontinuation
and most baseline case-mix variables were highly variable.
A higher adjusted hazard ratio for discontinuation was ob-
served for patients with psychiatric disorder (HR = 1.75
[95% CI = 1.15–2.66]) (Table 3). In time-varying Cox re-
gression analyses, higher adjusted hazard ratios for discon-
tinuation were observed for lower PTH in the previous
month (< 150 pg/ml vs. 150–299, HR = 2.57 [95% CI =
1.52–4.33]) and lower serum calcium levels in the previous
month (7.50–8.39mg/dl vs. 8.40–10.19, HR = 1.65 [95% CI
= 1.04–2.60]; < 7.50, HR = 1.83 [95% CI = 0.83–4.04]). Pa-
tients with low serum phosphorus in the previous month
(< 3.50 vs 3.50–5.49, HR = 1.58 [95% CI = 1.09–2.30]) or
who were hospitalized in the prior 3months (HR = 1.40;
95% CI = 1.01–1.92) were also more likely to have cinacal-
cet prescription discontinued.
Cinacalcet reinitiation in the newly-discontinued-user
cohort
We identified 415 patients in our newly-discontinued-u-
ser cohort. During 2964months of follow-up, cinacalcet
was reinitiated in 171 patients (Table 1, right panel). The
overall reinitiation rate was 0.058/month and ranged
two-fold across countries, from 0.046/month in Sweden
Table 1 Crude rates of cinacalcet discontinuation and reinitiation, overall and by country
Discontinuation in new-user cohort Reinitiation in newly-discontinued-user cohort
N Months at risk Discontinuations Crude ratea N Months at risk Reinitiations Crude ratea
Europe 613 5454 172 0.032 415 2964 171 0.058
Belgium 18 112 5 0.045 14 104 5 0.048
France 60 462 13 0.028 34 207 11 0.053
Germany 108 1128 30 0.027 74 617 30 0.049
Italy 149 1465 53 0.036 140 1129 67 0.059
Spain 147 1192 41 0.034 85 472 27 0.057
Sweden 68 580 12 0.021 30 196 9 0.046
UK 63 515 18 0.035 38 239 22 0.092
aEach crude rate was computed as the number of outcome events observed during follow-up (discontinuations or reinitiations), divided by the number of person-
months at risk. Thus, each rate is expressed per month
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to 0.092/month in the UK. The overall proportion of pa-
tients reinitiating cinacalcet was 38% after 6 months and
49% after 12 months; variability across countries at 12
months ranged from 35% in Belgium to 64% in the UK
(Fig. 3). Patients who reinitiated cinacalcet treatment
after a discontinuation had longer median dialysis vin-
tage, were more likely to be female, and lower % with
lung disease, but higher median PTH levels at start of
discontinuation [310 (IQR: 145, 575) vs 237 (IQR: 117,
518) pg/ml].
Baseline variables were not strongly associated with
cinacalcet reinitiation, except for high calcium levels
(10.20+ mg/dl vs. 8.4–10.19, HR = 2.04 [95% CI = 1.28–
3.25]) (Table 4). Lower reinitiation rates were associated
with very low values in the prior month of serum phos-
phorus (< 3.50 mg/dl vs. 3.50–5.49, HR = 0.40 [95% CI =
0.24–0.66]) and albumin (< 3.20 g/dl vs. 3.80+, HR = 0.49
[95% CI = 0.26–0.92]). Higher reinitiation rates were
most strongly associated with higher PTH in the previ-
ous month (300–599 pg/ml vs. 150–299, HR = 1.88 [95%
CI = 1.19–2.97]; 600+ pg/ml, HR = 3.02 [95% CI = 1.92–
4.76]).
Post-discontinuation trends in CKD-MBD biomarkers
During the 12month follow-up period after cinacalcet
discontinuation, mean serum PTH levels increased, from
408 pg/ml (95% CI = 356–460) to 510 pg/ml (95% CI =
442–579) in the newly-discontinued-user cohort (Fig. 4;
data table in Additional file 1: Table S1). Mean serum
calcium levels increased from 9.12 mg/dl (95% CI =
9.02–9.22) to 9.22 mg/dl (95% CI = 9.10–9.35) within the
first 6 months before declining to 9.06 mg/dl (95% CI =
8.91–9.21) at month 12. Throughout follow-up, mean
serum phosphorus levels remained in the range of 4.9–
5.1 mg/dl. Analyses restricted to patients with 12months
of cinacalcet-free follow-up did not reveal substantial
differences in these trends.
Discussion
We found that cinacalcet prescriptions were discontin-
ued in 21 and 35% of European hemodialysis patients
within 6 and 12months, respectively. Among patients
who discontinued cinacalcet after at least 3 months of
prescription, nearly 50% returned to therapy within 12
months. We observed strong associations of levels of
PTH and serum calcium in the previous month with
both cinacalcet prescription discontinuation and reinitia-
tion, but such associations were not observed with most
variables measured at baseline. Patients with a discontin-
ued cinacalcet prescription experienced a sustained sub-
sequent increase in mean PTH levels, a small and
temporary increase in serum calcium levels, and no
change in serum phosphorus levels.
Our estimates of the proportion of patients with dis-
continued or reinitiated cinacalcet prescription are simi-
lar to other reports from Europe and the U.S. based on
prescriptions entered into the medical record. In the US,
Kilpatrick et al. [22] reported 20 and 30% cinacalcet dis-
continuation at 6 and 12months, respectively, and 50%
for reinitiation at 12 months. In a multi-center cohort of
European hemodialysis patients treated at a single chain
provider, de Francisco et al. [25] observed a slightly
lower rate of discontinuation, 23% of patients within 1
year, based on a different definition of discontinuation
(defined as > 45 prescription-free days). However, our re-
sults more closely align with their sensitivity analyses in
Fig. 2 Proportion of patients discontinuing cinacalcet during follow-up (new-user cohort; n = 613). The solid line represents Europe overall, and
the dashed lines denote individual countries
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which discontinuation was identified as the start of a
90-day period in which at least 60 days were
prescription-free. Using the alternate definition, they
found approximately 35% of patients discontinued cina-
calcet within 1 year.
In the 12months after discontinuation of cinacalcet,
we observed a sustained trend of increasing PTH levels
that stands in contrast to the modest increase (with
gradual return to baseline) in calcium levels and gener-
ally stable phosphorus levels. Although we did not
attempt to adjust our estimates of post-discontinuation
CKD-MBD laboratory value trajectories for changes in
IV or oral vitamin D agents that would influence labora-
tory values and might trigger cinacalcet reinitiation (and
therefore censoring from the analysis), we found no sub-
stantial differences in laboratory value trajectories when
excluding patients who restarted cinacalcet within 12
months. Our laboratory findings are consistent with the
results of a European cohort study of incident
hemodialysis patients from 2007 to 2009 that showed a
Table 2 Selected characteristics of patients at start of follow-up, by analysis cohort
New-user cohort Newly-discontinued-user cohort
Discontinued cinacalcet Did not discontinue Reinitiated cinacalcet Did not reinitiate
N 172 441 171 244
Age (yrs) 62.8 (16.9) 61.9 (15.6) 63.6 (14.8) 63.5 (15.8)
Time on dialysis (yrs) [median/IQR] 3.9 [1.8, 7.1] 3.7 [1.7, 7.0] 5.1 [2.7, 9.6] 4.5 [2.4, 8.5]
Male (%) 60.5 62.1 52.0 58.9
Coronary artery disease (%) 31.6 26.1 28.2 32.9
Cancer (%) 16.4 11.7 14.8 12.6
Other cardiovascular disease (%) 24.0 27.1 25.9 28.9
Cerebrovascular disease (%) 16.5 11.2 13.6 14.2
Congestive heart failure (%) 15.8 12.2 12.9 15.5
Diabetes (%) 28.7 29.6 27.8 31.1
GI Bleeding (%) 2.9 3.4 4.1 5.0
Hypertension (%) 86.5 88.5 87.6 86.3
Lung disease (%) 16.5 11.9 9.5 15.5
Psychiatric disorder (%) 21.6 11.5 17.1 21.8
Peripheral vascular disease (%) 31.6 24.8 27.6 30.1
Hospitalized in baseline period (%) 18.0 16.1 15.8 18.7
BMI (kg/m2) 25.9 (5.3) 26.5 (5.2) 26.2 (5.3) 26.2 (5.4)
Serum phosphorus (mg/dl) 5.3 (1.7) 5.4 (1.5) 5.1 (1.7) 5.1 (1.6)
Serum PTH (pg/ml) [median/IQR] 430 [317, 749] 507 [340, 780] 310 [145, 575] 237 [117, 518]
Serum total calcium (mg/dl) 9.1 (0.9) 9.3 (0.8) 9.0 (0.9) 8.9 (0.8)
Serum albumin (g/dl) 3.8 (0.4) 3.8 (0.5) 3.8 (0.5) 3.7 (0.5)
Phosphate binder use (%)
No phosphate binder use 17.5 15.8 15.5 18.0
Ca-containing only 7.0 12.3 13.1 11.7
Non-Ca-containing only 57.9 53.3 54.2 49.4
Both 17.5 18.6 17.3 20.9
Vitamin D (active/analog) use (%)
No vitamin D use 42.9 37.5 34.5 42.3
IV vitamin D only 29.4 30.1 31.6 27.2
Oral vitamin D only 25.9 32.4 32.1 29.3
Both 1.8 0.0 1.8 1.3
New-user cohort patients required at least 3 consecutive months without cinacalcet prescription prior to starting cinacalcet. Newly-discontinued-user cohort
patients required at least 3 consecutive months with cinacalcet prescription prior to discontinuing cinacalcet. Values represent mean (standard error) unless noted
otherwise. Comorbidities were measured at DOPPS study entry; all other values were measured at the end of the baseline period prior to the start of follow-up for
each cohort. Psychiatric disorder includes depression, bipolar disorder, schizophrenia, and alcohol or substance abuse
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Table 3 Estimated effects (crude and adjusted hazard ratios [HR] and 95% confidence intervals [CI]) of patient predictors on
cinacalcet discontinuation, by type of predictor (baseline or time-dependent), in the new-user cohort (n = 613)
Baseline Time-dependent
Crude Adjusteda Crude Adjusted a
Variable HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age (yrs)
< 45 1.20 (0.74, 1.92) 1.36 (0.81, 2.30)
45–54 0.78 (0.43, 1.39) 0.83 (0.46, 1.49)
55–64 1 (ref) 1 (ref)
65–74 0.97 (0.65, 1.47) 0.85 (0.52, 1.40)
75+ 1.48 (0.96, 2.26) 1.36 (0.83, 2.22)
Vintage (yrs)
< 1.0 0.78 (0.43, 1.42) 0.79 (0.44, 1.42)
1.0–2.9 1 (ref) 1 (ref)
3.0–4.9 1.16 (0.78, 1.71) 1.09 (0.74, 1.63)
5.0+ 0.92 (0.64, 1.33) 0.87 (0.59, 1.28)
BMI (kg/m2)
< 18.5 1.49 (0.75, 2.96) 1.31 (0.58, 2.97)
18.5–24.9 1.44 (1.01, 2.07) 1.56 (1.05, 2.30)
25.0–29.9 1 (ref) 1 (ref)
30.0+ 1.17 (0.74, 1.85) 1.30 (0.80, 2.12)
Male sex 0.98 (0.73, 1.32) 0.94 (0.67, 1.30)
Coronary artery disease 1.48 (1.08, 2.03) 1.26 (0.90, 1.74)
Cancer 1.40 (0.95, 2.04) 1.31 (0.91, 1.89)
Other cardiovascular disease 1.20 (0.80, 1.79) 1.06 (0.67, 1.68)
Cerebrovascular disease 1.53 (1.03, 2.27) 1.39 (0.93, 2.06)
Congestive heart failure 1.51 (1.02, 2.25) 1.21 (0.79, 1.85)
Diabetes 0.99 (0.71, 1.38) 0.87 (0.57, 1.32)
GI bleeding 0.94 (0.47, 1.86) 0.76 (0.33, 1.73)
Hypertension 0.88 (0.59, 1.30) 0.77 (0.48, 1.23)
Lung disease 1.30 (0.83, 2.03) 1.15 (0.73, 1.80)
Psychiatric disorder 1.91 (1.29, 2.81) 1.75 (1.15, 2.66)
Peripheral vascular disease 1.40 (1.00, 1.95) 1.24 (0.88, 1.74)
Hospitalization in prior 3 months 1.26 (0.85, 1.87) 1.21 (0.79, 1.84) 1.58 (1.13, 2.20) 1.40 (1.01, 1.92)
Serum phosphorus (mg/dl)
< 3.50 1.31 (0.78, 2.20) 1.39 (0.78, 2.49) 1.61 (1.11, 2.34) 1.58 (1.09, 2.30)
3.50–5.49 1 (ref) 1 (ref) 1 (ref) 1 (ref)
5.50–5.99 1.50 (1.02, 2.19) 1.43 (0.97, 2.11) 1.43 (0.87, 2.35) 1.36 (0.83, 2.21)
6.00+ 0.97 (0.70, 1.35) 1.03 (0.73, 1.47) 1.05 (0.70, 1.58) 1.04 (0.69, 1.57)
Serum PTH (pg/ml)
< 150 2.90 (1.52, 5.12) 2.26 (1.24, 4.12) 2.24 (1.39, 3.59) 2.57 (1.52, 4.33)
150–299 1 (ref) 1 (ref) 1 (ref) 1 (ref)
300–599 1.51 (0.90, 2.55) 1.47 (0.86, 2.52) 0.77 (0.48, 1.25) 0.84 (0.52, 1.38)
600+ 1.60 (0.92, 2.81) 1.50 (0.85, 2.64) 0.93 (0.58, 1.50) 0.96 (0.58, 1.57)
Serum calcium (mg/dl)
< 7.50 1.51 (0.67, 3.39) 1.43 (0.56, 3.68) 1.97 (0.89, 4.38) 1.83 (0.83, 4.04)
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Table 3 Estimated effects (crude and adjusted hazard ratios [HR] and 95% confidence intervals [CI]) of patient predictors on
cinacalcet discontinuation, by type of predictor (baseline or time-dependent), in the new-user cohort (n = 613) (Continued)
Baseline Time-dependent
Crude Adjusteda Crude Adjusted a
Variable HR 95% CI HR 95% CI HR 95% CI HR 95% CI
7.50–8.39 1.54 (1.03, 2.31) 1.56 (0.99, 2.45) 1.68 (1.11, 2.54) 1.65 (1.04, 2.60)
8.40–10.19 1 (ref) 1 (ref) 1 (ref) 1 (ref)
10.20+ 0.91 (0.55, 1.50) 0.90 (0.52, 1.55) 1.06 (0.57, 1.99) 1.03 (0.52, 2.06)
Serum albumin (g/dl)
< 3.20 0.91 (0.49, 1.67) 0.82 (0.46, 1.46) 1.26 (0.69, 2.29) 1.22 (0.69, 2.15)
3.20–3.49 1.17 (0.74, 1.85) 1.10 (0.67, 1.80) 0.98 (0.57, 1.68) 0.96 (0.55, 1.67)
3.50–3.79 1.14 (0.81, 1.61) 1.16 (0.81, 1.66) 1.08 (0.75, 1.54) 1.19 (0.80, 1.76)
3.80+ 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Phosphate binder use
None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Ca-containing only 0.60 (0.28, 1.31) 0.51 (0.25, 1.08) 0.75 (0.38, 1.51) 0.54 (0.27, 1.08)
Non-Ca-containing only 0.97 (0.62, 1.54) 0.91 (0.58, 1.44) 1.00 (0.65, 1.56) 0.94 (0.60, 1.49)
Both 0.97 (0.56, 1.69) 0.79 (0.45, 1.40) 0.79 (0.44, 1.40) 0.64 (0.36, 1.13)
Vitamin D use
None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
IV vitamin D only 0.95 (0.66, 1.38) 1.00 (0.66, 1.51) 1.30 (0.91, 1.85) 1.36 (0.91, 2.03)
Oral vitamin D only 0.76 (0.51, 1.15) 0.83 (0.56, 1.22) 1.17 (0.76, 1.79) 1.12 (0.70, 1.79)
aAdjusted for baseline covariates: age, vintage, 13 summary comorbid conditions, body mass index, and male sex. Separate models estimated for each variable
shown. Time-dependent effects estimated only for variables shown. Psychiatric disorder includes depression, bipolar disorder, schizophrenia, and alcohol or
substance abuse
Fig. 3 Proportion of patients reinitiating cinacalcet during follow-up (newly-discontinued-user cohort; n = 415). The solid line represents Europe
overall, and the dashed lines denote individual countries
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Table 4 Estimated effects (crude and adjusted hazard ratios [HR] and 95% confidence intervals [CI]) of patient predictors on
cinacalcet reinitiation, by type of predictor (baseline or time-dependent), in the newly-discontinued-user cohort (n = 415)
Baseline Time-dependent
Crude Adjusteda Crude Adjusted a
Variable HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age (yrs)
< 45 0.91 (0.53, 1.54) 0.87 (0.49, 1.54)
45–54 0.90 (0.57, 1.42) 1.01 (0.60, 1.71)
55–64 1 (ref) 1 (ref)
65–74 0.98 (0.64, 1.51) 0.96 (0.58, 1.61)
75+ 1.05 (0.71, 1.56) 0.93 (0.59, 1.45)
Vintage (yrs)
< 1.0 1.35 (0.74, 2.46) 1.70 (0.86, 3.37)
1.0–2.9 1 (ref) 1 (ref)
3.0–4.9 1.17 (0.76, 1.80) 1.26 (0.77, 2.07)
5.0+ 1.23 (0.79, 1.92) 1.25 (0.76, 2.05)
BMI (kg/m2)
< 18.5 1.20 (0.54, 2.65) 1.21 (0.54, 2.71)
18.5–24.9 1.21 (0.82, 1.78) 1.19 (0.79, 1.79)
25.0–29.9 1 (ref) 1 (ref)
30.0+ 1.00 (0.69, 1.46) 1.08 (0.71, 1.63)
Male sex 0.90 (0.68, 1.19) 0.84 (0.58, 1.22)
Coronary artery disease 0.95 (0.67, 1.34) 0.90 (0.59, 1.38)
Cancer 1.32 (0.86, 2.04) 1.28 (0.78, 2.09)
Other cardiovascular disease 0.96 (0.72, 1.30) 0.98 (0.70, 1.35)
Cerebrovascular disease 1.23 (0.78, 1.94) 1.18 (0.69, 2.00)
Congestive heart failure 0.96 (0.61, 1.51) 0.99 (0.58, 1.69)
Diabetes 0.92 (0.65, 1.29) 0.99 (0.69, 1.41)
GI bleeding 0.89 (0.45, 1.78) 0.94 (0.41, 2.16)
Hypertension 1.06 (0.72, 1.56) 1.23 (0.79, 1.90)
Lung disease 0.77 (0.51, 1.18) 0.73 (0.45, 1.19)
Psychiatric disorder 0.92 (0.62, 1.35) 0.94 (0.63, 1.41)
Peripheral vascular disease 1.11 (0.80, 1.54) 1.21 (0.83, 1.75)
Hospitalization in prior 3 months 0.83 (0.54, 1.28) 0.76 (0.45, 1.30) 0.77 (0.52, 1.14) 0.82 (0.54, 1.24)
Serum phosphorus (mg/dl)
< 3.50 0.86 (0.58, 1.28) 0.84 (0.54, 1.31) 0.40 (0.24, 0.67) 0.40 (0.24, 0.66)
3.50–5.49 1 (ref) 1 (ref) 1 (ref) 1 (ref)
5.50–5.99 0.75 (0.41, 1.36) 0.68 (0.40, 1.18) 1.42 (0.91, 2.24) 1.27 (0.85, 1.89)
6.00+ 1.06 (0.76, 1.49) 1.03 (0.72, 1.49) 1.01 (0.69, 1.49) 1.05 (0.70, 1.56)
Serum PTH (pg/ml)
< 150 0.90 (0.60, 1.33) 0.87 (0.54, 1.41) 1.35 (0.80, 2.27) 1.39 (0.84, 2.31)
150–299 1 (ref) 1 (ref) 1 (ref) 1 (ref)
300–599 1.26 (0.81, 1.96) 1.39 (0.84, 2.31) 1.77 (1.15, 2.71) 1.88 (1.19, 2.97)
600+ 1.19 (0.75, 1.87) 1.23 (0.72, 2.09) 2.99 (1.91, 4.69) 3.02 (1.92, 4.76)
Serum calcium (mg/dl)
< 7.50 0.60 (0.17, 2.11) 0.66 (0.18, 2.38) 0.51 (0.17, 1.51) 0.49 (0.15, 1.62)
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Table 4 Estimated effects (crude and adjusted hazard ratios [HR] and 95% confidence intervals [CI]) of patient predictors on
cinacalcet reinitiation, by type of predictor (baseline or time-dependent), in the newly-discontinued-user cohort (n = 415) (Continued)
Baseline Time-dependent
Crude Adjusteda Crude Adjusted a
Variable HR 95% CI HR 95% CI HR 95% CI HR 95% CI
7.50–8.39 1.13 (0.78, 1.63) 1.15 (0.78, 1.70) 1.05 (0.70, 1.56) 1.03 (0.67, 1.58)
8.40–10.19 1 (ref) 1 (ref) 1 (ref) 1 (ref)
10.20+ 2.06 (1.32, 3.20) 2.04 (1.28, 3.25) 1.26 (0.84, 1.88) 1.24 (0.80, 1.93)
Serum albumin (g/dl)
< 3.20 0.64 (0.40, 1.02) 0.61 (0.36, 1.02) 0.51 (0.30, 0.87) 0.49 (0.26, 0.92)
3.20–3.49 0.70 (0.44, 1.10) 0.60 (0.37, 0.98) 0.98 (0.67, 1.43) 0.97 (0.66, 1.43)
3.50–3.79 0.90 (0.66, 1.24) 0.89 (0.63, 1.25) 0.96 (0.67, 1.37) 0.95 (0.64, 1.39)
3.80+ 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Phosphate binder use
None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Ca-containing only 1.02 (0.59, 1.75) 1.21 (0.68, 2.15) 0.90 (0.55, 1.48) 0.91 (0.53, 1.54)
Non-Ca-containing only 1.30 (0.83, 2.04) 1.37 (0.82, 2.28) 1.55 (1.07, 2.24) 1.50 (1.06, 2.12)
Both 1.15 (0.72, 1.85) 1.22 (0.69, 2.15) 1.19 (0.75, 1.89) 1.20 (0.72, 1.99)
Vitamin D use
None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
IV vitamin D only 1.05 (0.72, 1.53) 0.95 (0.64, 1.43) 0.91 (0.61, 1.35) 0.87 (0.57, 1.33)
Oral vitamin D only 1.16 (0.81, 1.67) 1.06 (0.75, 1.50) 1.01 (0.71, 1.43) 0.94 (0.67, 1.31)
Both 0.86 (0.37, 2.02) 0.97 (0.46, 2.02) 0.61 (0.18, 2.08) 0.70 (0.21, 2.30)
aAdjusted for baseline covariates: age, vintage, 13 summary comorbid conditions, body mass index, and male sex. Separate models estimated for each variable
shown. Time-dependent effects estimated only for variables shown. Psychiatric disorder includes depression, bipolar disorder, schizophrenia, and alcohol or
substance abuse
Fig. 4 Observed monthly means and LOESS (LOcal regrESSion, or locally-weighted scatterplot smoothing) of a parathyroid hormone (PTH, n =
357), b total calcium (n = 346), and c phosphorus (n = 366) in the newly-discontinued-user cohort. Follow-up time began with the first monthly
record after the discontinuation and was censored at reinitiation of cinacalcet treatment (prescription) or loss to follow-up for any reason. Errors
bars denote 95% confidence intervals for the mean at each month
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sustained (but faster) PTH increase over 12 months and
similarly modest trends in calcium and phosphorus
levels [25]. In contrast, a study of US Medicare claims
from 2007 to 2010 linked with clinical data from a large
dialysis provider reported an initial PTH increase after
cinacalcet discontinuation that returned to baseline, and
an increase in calcium levels that was sharp and sus-
tained [24]. The reasons for this juxtaposition of results
are unclear. A patient’s failure to take cinacalcet as pre-
scribed (non-adherence), which was not directly cap-
tured in our study, would result in delayed capture of
removal of cinacalcet from the patient’s medication list
(discontinuation, as defined in our study). In this case,
the immediate effect of discontinuing cinacalcet on
levels of CKD-MBD biomarkers may have already oc-
curred by the observed time of discontinuation, thus
diminishing the potential for observing stronger
post-discontinuation trends. Additionally, the observed
trends may be impacted by our choice to censor patients
at the reinitiation of cinacalcet; patients with greatly in-
creased PTH levels would be excluded in later follow-up
months, potentially restricting the observable magnitude
of change among the remaining patients. We also note
that our study includes more recent data through 2015
that may reflect changes in the international CKD-MBD
clinical practice guidelines for SHPT management pub-
lished in 2009 that liberalized the upper maintenance
range for PTH [7, 26].
In our study, we found time-varying PTH levels to
be highly associated with discontinuation and reinitia-
tion of cinacalcet. Our finding of an increased rate of
discontinuation at PTH < 150 pg/ml is consistent with
the lower PTH target suggested by current inter-
national guidelines for hemodialysis patients (2 to 9
times the upper normal limit, approximately 130–585
pg/ml) [25] and with approved prescribing informa-
tion for cinacalcet [10]. Similarly, our findings of an
increasingly stronger association with increasingly
higher PTH levels above 300 pg/ml with cinacalcet
reinitiation align with PTH upper limits in European
countries in the DOPPS. In DOPPS 5, 89% of facilities
reported using an upper limit of 300 pg/ml or higher
with a median upper limit among all facilities of 450
pg/ml [7]. Very low serum calcium levels < 7.5 mg/dl
though uncommon were associated with a higher ad-
justed rate of discontinuation (HR: 1.83; 95% CI: 0.83–
4.04) compared to patients having a serum calcium
level of 8.4–10.2 mg/dl. Higher risk of discontinuation
was also seen for moderately low calcium levels be-
tween 7.5 and 8.4 mg/dl (HR: 1.65, 95% CI: 1.04–2.60).
Hypocalcemia is a contraindication for cinacalcet pre-
scription [10], but a report from Brunelli, et al. sug-
gested that in most patients, calcium levels typically
returned to normal levels within 90 days regardless of
directed therapeutic intervention [9]; see also Floege
et al. [27].
Patient factors may also increase the likelihood that
cinacalcet therapy is discontinued. Physicians may dis-
continue (or choose not to reinitiate) cinacalcet for
symptomatic patients who appear to be malnourished or
undernourished (e.g. based upon low serum phosphorus
or albumin levels) due to gastrointestinal side effects as-
sociated with cinacalcet use. Unfortunately, our study
did not collect longitudinal data on these side effects
that could be used to assess their direct (i.e.,
non-adherence) and/or indirect (e.g. the patient reports
negative side effects to the physician, who then termi-
nates the prescription) influence on cinacalcet discon-
tinuation. Additionally, we found that patients
hospitalized within the prior 3 months both discontinued
cinacalcet more often (HR = 1.40; 95% CI = 1.01–1.92)
and reinitiated less often (HR = 0.82; 95% CI = 0.54–
1.24). It is possible that during these periods of time,
medication reconciliation is suboptimal and lapses occur
for the refilling of oral medications, including cinacalcet.
Thus, targeted use of home medication monitoring pro-
grams and cross-provider strategies to promote continu-
ity of care during episodes of hospitalization may reduce
the opportunity for PTH values to vary outside of target
levels [28, 29]. Furthermore, the recent availability of
etelcalcetide [30], a second-generation calcimimetic, can
provide physicians with an option for reducing PTH
levels as well or better than cinacalcet. Etelcalcetide is
intravenously administered at the end of the dialysis ses-
sion, potentially helping to improve adherence [31].
Our study benefits from its nationally representative se-
lection of dialysis facilities and patients to provide
generalizable and contemporary results for hemodialysis
practice across seven European countries. However, our
data collection protocol was limited to prescription infor-
mation available in a patient’s medical chart. Thus, we
were unable to directly identify patient-initiated discon-
tinuation, including failure to take medication at pre-
scribed dose or frequency (i.e., non-adherence) or failure
to fill or refill a cinacalcet prescription, that occurred be-
fore the cinacalcet prescription was removed from the
medication list. Likewise, our monthly ascertainment of
cinacalcet prescription as a binary variable (active/absent)
conservatively assumes an active prescription covered the
entire month. Therefore, our results likely underestimate
the true rates of cinacalcet discontinuation and the poten-
tial magnitude of post-discontinuation trends in
CKD-MBD biochemistries.
Conclusions
In summary, discontinuation of cinacalcet prescription,
based on dialysis facility medical records, is common in
European countries, occurring in approximately 35% of
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patients within 1 year. Given the observed rise in PTH
after cinacalcet discontinuation, additional research is
needed to identify optimal cinacalcet treatment strat-
egies for SHPT management, including a comparison of
intermittent cinacalcet therapy versus sustained treat-
ment with reduced dose or frequency.
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